RGEDF (Chemical Works of Gedeon Richter) Operating Income : $370 Mil (TTM As of Mar. 2025)

View and export this data going back to 2007. Start your Free Trial

What is Chemical Works of Gedeon Richter Operating Income?

Chemical Works of Gedeon Richter's Operating Income for the three months ended in Mar. 2025 was $193 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2025 was $370 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Chemical Works of Gedeon Richter's Operating Income for the three months ended in Mar. 2025 was $193 Mil. Chemical Works of Gedeon Richter's Revenue for the three months ended in Mar. 2025 was $638 Mil. Therefore, Chemical Works of Gedeon Richter's Operating Margin % for the quarter that ended in Mar. 2025 was 30.26%.

Good Sign:

Chemical Works of Gedeon Richter PLC operating margin is expanding. Margin expansion is usually a good sign.

Chemical Works of Gedeon Richter's 5-Year average Growth Rate for Operating Margin % was 23.10% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Chemical Works of Gedeon Richter's annualized ROC % for the quarter that ended in Mar. 2025 was 16.68%. Chemical Works of Gedeon Richter's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2025 was 69.55%.

Chemical Works of Gedeon Richter Operating Income Historical Data

The historical data trend for Chemical Works of Gedeon Richter's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chemical Works of Gedeon Richter Operating Income Chart

Chemical Works of Gedeon Richter Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Operating Income

Get a 7-Day Free Trial

323.92

385.87

432.78

540.49

744.40

Chemical Works of Gedeon Richter Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Dec24	Mar25
Operating Income	Get a 7-Day Free Trial															128.06	181.50	176.89	-	193.02

Chemical Works of Gedeon Richter Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $370 Mil.

Chemical Works of Gedeon Richter (OTCPK:RGEDF) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Chemical Works of Gedeon Richter's annualized ROC % for the quarter that ended in Mar. 2025 is calculated as:

	ROC % (Q: Mar. 2025 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2024 )	+	Invested Capital (Q: Mar. 2025 ))	/ count )
=	772.064 * ( 1 - 16.84% )	/	( (3850.97	+	3846.063)	/ 2 )
=	642.0484224	/	3848.5165
=	16.68 %

where

	Invested Capital		(Q: Dec. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	4564.411	-	324.422	-	( 389.019	-	max(0, 498.99	-	1825.368	+	389.019	))
=	3850.97

	Invested Capital		(Q: Mar. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	4635.173	-	214.543	-	( 574.567	-	max(0, 451.293	-	2026.769	+	574.567	))
=	3846.063

Note: The Operating Income data used here is four times the quarterly (Mar. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Chemical Works of Gedeon Richter's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2025 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2025 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2024		Q: Mar. 2025
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	1400.848	/	( ( (1078.779 + max(872.383, 0))	+	(1078.491 + max(998.798, 0)) )	/	2 )
=	1400.848	/	( ( 1951.162	+	2077.289 )	/	2 )
=	1400.848	/	2014.2255
=	69.55 %

where Working Capital is:

	Working Capital		(Q: Dec. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(684.315	+	613.369	+	51.377)	-	(324.422	+	0	+	152.256)
=	872.383

	Working Capital		(Q: Mar. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(669.312	+	637.774	+	126.627)	-	(214.543	+	0	+	220.372)
=	998.798

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2025) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Chemical Works of Gedeon Richter's Operating Margin % for the quarter that ended in Mar. 2025 is calculated as:

Operating Margin %	=	Operating Income (Q: Mar. 2025 )	/	Revenue (Q: Mar. 2025 )
	=	193.016	/	637.894
	=	30.26 %

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.

Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.

Chemical Works of Gedeon Richter Operating Income Related Terms

Thank you for viewing the detailed overview of Chemical Works of Gedeon Richter's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Chemical Works of Gedeon Richter Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Chemical Works of Gedeon Richter PLC (OTCPK:RGEDF) » Definitions » Operating Income

Traded in Other Exchanges

RICHTER:Hungary 0QFP:UK RIG2:Germany RIG2:Germany

Address

Gyomroi ut 19-21, Budapest, HUN, 1103

Website

https://www.gedeonrichter.com/hu-hu

Chemical Works of Gedeon Richter PLC is a pharmaceutical company. The company focuses on the development and manufacture of gynaecological, cardiovascular, and central nervous system products. It manufactures medicines including original, generic and licensed products for treatment in the therapeutic area. The group is active in two business segments namely, the Pharma segment comprising Women's Healthcare, Neuropsychiatry, Biotechnology, General Medicine, and Other pharma; and the Others segment includes the remaining wholesale and retail business of the Group and all other activities. The company operates internationally.